Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US11219614B2 · kind B2 · utility
5Cited by
4References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 1, 2017 |
| Grant date | Jan 11, 2022 |
| Priority date | — |
| Expiry date | Sep 1, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating cancer in a subject includes administering an active agent selected from ascorbic acid, an ascorbic acid derivative, and/or a pharmaceutically acceptable salt thereof and administering a pentaaza macrocyclic ring complex corresponding to formula (I) below:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.